Market Closed -
Nasdaq
04:00:00 2024-05-24 pm EDT
|
5-day change
|
1st Jan Change
|
15.78
USD
|
-0.06%
|
|
-1.25%
|
-1.62%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,434
|
1,256
|
1,199
|
924.6
|
1,028
|
985.4
|
-
|
-
|
Enterprise Value (EV)
1 |
1,460
|
1,395
|
1,392
|
1,174
|
1,281
|
1,210
|
1,130
|
1,049
|
P/E ratio
|
9.9
x
|
-
|
-
|
5.59
x
|
-
|
-
|
-
|
-
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
5.49
x
|
3.73
x
|
3.06
x
|
2.79
x
|
3.31
x
|
3.2
x
|
2.95
x
|
2.74
x
|
EV / Revenue
|
5.6
x
|
4.14
x
|
3.55
x
|
3.54
x
|
4.13
x
|
3.93
x
|
3.38
x
|
2.92
x
|
EV / EBITDA
|
5.61
x
|
4.17
x
|
3.58
x
|
5.31
x
|
-
|
10.4
x
|
8.62
x
|
7.92
x
|
EV / FCF
|
5,672,594
x
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
0%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
4.57
x
|
2.33
x
|
2.89
x
|
1.62
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
101,279
|
101,392
|
69,492
|
69,783
|
64,087
|
62,445
|
-
|
-
|
Reference price
2 |
14.16
|
12.39
|
17.25
|
13.25
|
16.04
|
15.78
|
15.78
|
15.78
|
Announcement Date
|
2/5/20
|
2/3/21
|
2/9/22
|
2/28/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
261
|
336.8
|
391.9
|
331.3
|
310.5
|
307.5
|
334.2
|
359.6
|
EBITDA
1 |
260.2
|
335
|
388.9
|
220.9
|
-
|
115.9
|
131.1
|
132.4
|
EBIT
1 |
246.4
|
321.1
|
375.1
|
207
|
135.7
|
98
|
113.1
|
114.5
|
Operating Margin
|
94.39%
|
95.35%
|
95.72%
|
62.47%
|
43.7%
|
31.87%
|
33.86%
|
31.84%
|
Earnings before Tax (EBT)
|
232.9
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
157.3
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
60.26%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
|
1.430
|
-
|
-
|
2.370
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
257.4
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
98.63%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
98.93%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
163.68%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/5/20
|
2/3/21
|
2/9/22
|
2/28/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
90.06
|
108.2
|
67.26
|
65.8
|
76.37
|
80.99
|
67.26
|
85.84
|
77.5
|
76.28
|
73.38
|
80.34
|
EBITDA
|
-
|
86.14
|
27.95
|
25.6
|
38.78
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
82.55
|
22.53
|
24.18
|
29.9
|
33.48
|
17.94
|
44.04
|
32.24
|
25.25
|
16.96
|
23.55
|
Operating Margin
|
-
|
76.28%
|
33.5%
|
36.75%
|
39.14%
|
41.34%
|
26.67%
|
51.3%
|
41.61%
|
33.11%
|
23.11%
|
29.31%
|
Earnings before Tax (EBT)
|
-
|
-
|
286.4
|
-
|
41.14
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-
|
-
|
265.5
|
-
|
34.86
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
394.79%
|
-
|
45.65%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
|
-
|
-
|
2.800
|
-0.9800
|
0.4200
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/27/22
|
7/27/22
|
11/9/22
|
2/28/23
|
5/9/23
|
8/2/23
|
11/1/23
|
2/29/24
|
5/8/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
26.3
|
139
|
193
|
249
|
253
|
224
|
145
|
63.2
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
0.101
x
|
0.4151
x
|
0.4966
x
|
1.129
x
|
-
|
1.934
x
|
1.104
x
|
0.4775
x
|
Free Cash Flow
|
257
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
67.3%
|
62.4%
|
55.7%
|
5.11%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
3.100
|
5.330
|
5.960
|
8.180
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
2.270
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
0.01
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
0%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/5/20
|
2/3/21
|
2/9/22
|
2/28/23
|
2/29/24
|
-
|
-
|
-
|
Last Close Price
15.78
USD Average target price
16
USD Spread / Average Target +1.39% Consensus |
1st Jan change
|
Capi.
|
---|
| -1.62% | 985M | | +38.51% | 727B | | +33.05% | 599B | | -6.23% | 354B | | +18.78% | 328B | | +1.35% | 277B | | +16.00% | 243B | | +8.09% | 205B | | -5.77% | 203B | | +6.19% | 164B |
Other Pharmaceuticals
|